Abstract: The present invention encompasses ATR inhibitor for use in the treatment of coronavirus infections, including COVID-19, alone or in combination with one or more additional therapeutic agents.

Abstract: The present invention encompasses ATR inhibitor for use in the treatment of virus infections, including SARS-CoV infections such as COVID-19, alone or in combination with one or more additional therapeutic agents.

Abstract: An ATM inhibitor can be used in the treatment of coronavirus infections, including COVID-19, alone or in combination with one or more additional therapeutic agents.

Abstract: The present invention provides novel peptide sequences for use in microbial transgluatminase-mediated, in particular mTG2-mediated bioconjugations, in particular for the manufacture of antibody-drug-conjugates. Further disclosed are bioconjugation methods employing mTG2 and the novel peptide sequence motifs of the invention. The present invention further provides proteins comprising the novel sequence motifs of the invention as well as polynucleotides encoding the same.

Abstract: A method for producing cast items in a casting method, wherein a charge of a conductive material is introduced into the sphere of influence of at least one alternating electromagnetic field, so that the charge is kept in a levitating state. The melt is poured into moulds in order to produce turbine blades, prostheses or turbocharger impellers.

Abstract: A measurement current (i) is injected into an active part (4) of an HTS superconductor. The active part is cooled, but not reservoirs (1, 2) from/to which the superconductor is wound. Only a fraction of the active part is exposed to a magnetic field for testing the electrical properties of the superconductor. Buffer devices (20a, 20b) prevent current sharing from outside the active part. The measurement current is injected where the residual magnetic field is at least 3 times lower than the magnetic field for testing, and/or the local critical current at the current injection locations is at least three times higher than the critical current at the magnetic field for testing. The electrical properties, e.g. the critical current, are tested by determining an integral of a voltage drop (U) across the active part, e.g. between two voltage pick-up elements (15a, 15b), as a function of measurement time (?).

Abstract: A method for manufacturing an HTS coated tape (34) includes providing a substrate tape (1), depositing a textured buffer layer (3) onto a front side (7) of the substrate tape, depositing an HTS layer (32) onto the front side, and depositing a functional layer (2) onto a bottom side (6) of the substrate tape. The functional layer exerts a mechanically deforming effect on the substrate tape opposing a mechanically deforming effect on the substrate tape exerted by the textured buffer layer deposited on the front. The functional layer is at least partially deposited before and/or during the depositing of the textured buffer layer. This permits an HTS coated tape, with which higher critical currents of the HTS layer are achieved, to be produced.

Abstract: A method for producing cast items in a casting method, wherein a charge of a conductive material is introduced into the sphere of influence of at least one alternating electromagnetic field, so that the charge is kept in a levitating state. The melt is poured into moulds in order to produce turbine blades, prostheses or turbocharger impellers.

Abstract: A tape type superconductor (1), extending in longitudinal direction (LD), includes a substrate tape (2), at least one buffer layer (3), a superconductor layer (4), and plural elongated barrier structures (5, 5a, 5b). The superconductor layer has a width WSL in a direction (WD) that is perpendicular to the longitudinal direction and runs parallel to a flat side (8) of the substrate tape. The tape type superconductor has a longitudinal length LTTS t, and the elongated barrier structures are oriented in parallel with the longitudinal direction. A respective barrier structure has a longitudinal length LBS, with LBS?0.20*WSL and LBS?0.20*LTTS. The barrier structures are distributed longitudinally, are located at least partially in the superconductor layer, and impede a superconducting current flow in width direction across a respective barrier structure. This tape type superconductor achieves high critical currents simply and over extended tape lengths with suppressed magnetization.

Abstract: A superconductor structure (10, 20, 30), having a first strip piece (1), a second strip piece (2) and a third strip piece (3). Each strip piece has a substrate (5) and a superconducting layer (6) deposited thereon. End sections of the second and third strip pieces are connected via a layer (7) made of a first normally conducting material to the first strip piece, the second and third strip pieces overlap with the first strip piece, the superconducting layers of the second and third strip pieces face the superconducting layer of the first strip piece, and a seam (4, 23, 24) with a defined path length is formed between the end sections of the second and third strip pieces. The seam extends over an extension region (8) of the superconductor structure. Splicing strip pieces together in this manner achieves a high current load capacity.

Abstract: A superconductor structure (10, 20, 30), having a first strip piece (1), a second strip piece (2) and a third strip piece (3). Each strip piece has a substrate (5) and a superconducting layer (6) deposited thereon. End sections of the second and third strip pieces are connected via a layer (7) made of a first normally conducting material to the first strip piece, the second and third strip pieces overlap with the first strip piece, the superconducting layers of the second and third strip pieces face the superconducting layer of the first strip piece, and a seam (4, 23, 24) with a defined path length is formed between the end sections of the second and third strip pieces. The seam extends over an extension region (8) of the superconductor structure. Splicing strip pieces together in this manner achieves a high current load capacity.

Abstract: The present invention provides novel peptide sequences for use in microbial transgluatminase-mediated, in particular mTG2-mediated bioconjugations, in particular for the manufacture of antibody-drug-conjugates. Further disclosed are bioconjugation methods employing mTG2 and the novel peptide sequence motifs of the invention. The present invention further provides proteins comprising the novel sequence motifs of the invention as well as polynucleotides encoding the same.

Abstract: The invention relates to a pharmaceutical composition comprising as active ingredient an effective amount of 2-Methyl-4,5-di-(methylsulfonyl)-benzoyl-guanidine, or derivatives thereof, for the prophylaxis and therapy of Type II diabetes mellitus, the Metabolic syndrome, diabetic nephropathy and/or neuropathy. Another object of the invention concerns the use of 2-Methyl-4,5-di-(methylsulfonyl)-benzoyl-guanidine, or derivatives thereof, for the enhancement of insulin sensitivity and the preservation or increase of ß-cell compensation.

Abstract: The invention relates to a pharmaceutical composition comprising as active ingredient an effective amount of 2-Methyl-4,5-di-(methylsulfonyl)-benzoyl-guanidine, or derivatives thereof, for the prophylaxis and therapy of Type II diabetes mellitus, the Metabolic syndrome, diabetic nephropathy and/or neuropathy. Another object of the invention concerns the use of 2-Methyl-4,5-di-(methylsulfonyl)-benzoyl-guanidine, or derivatives thereof, for the enhancement of insulin sensitivity and the preservation or increase of ?-cell compensation.

Abstract: The invention relates to substituted dihydroquinazolines and to processes for their preparation and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for use as antiviral agents, in particular against cytomegalo viruses.

Abstract: The invention relates to dihydroquinazolines and methods for the production thereof, the use thereof in the treatment and/or prophylaxis of diseases, in addition to the use thereof in the production of medicaments in the treatment and/or prophylaxis of diseases, especially for use as anti-viral agents, especially against cytomegalo viruses.

Abstract: The invention relates to a pharmaceutical composition comprising as active ingredient an effective amount of 2-Methyl-4,5-di-(methylsulfonyI)-benzoyl-guanidine, or derivatives thereof, for the prophylaxis and therapy of Type II diabetes mellitus, the Metabolic syndrome, diabetic nephropathy and/or neuropathy. Another object of the invention concerns the use of 2-Methyl-4,5-di-(methylsulfonyl)-benzoyl-guanidine, or derivatives thereof, for the enhancement of insulin sensitivity and the preservation or increase of ?-cell compensation.

Abstract: The invention relates to the topical application of substituted thiazolyl amides in the treatment of herpes infections in humans, to preparations suitable for the topical application and to the production thereof.

Abstract: The invention relates to substituted dihydroquinazolines and to processes for their preparation and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for use as antiviral agents, in particular against cytomegalo viruses.

Abstract: The invention relates to substituted dihydroquinazolines and to processes for their preparation and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for use as antiviral agents, in particular against cytomegalo viruses.